In accordance with this, it has been recently included in the World Health Organization (WHO) diagnostic criteria for Philadelphia chromosome negative myeloid neoplasms [5].Furthermore, pharmacological JAK2 inhibitors are a new type of treatment for myelofibrosis and potentially other types of myeloid neoplasms as well [25]–[27], reinforcing the need for a convenient tool to detect this mutation. Here, JAK2 is linked to myeloid neoplasm.